SCHEMBL10325337

SCHEMBL10325337

O=C(O)c1ccc(-c2ncccc2F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.56
TRPV1 Q8NER1 1/20 0.56
MKNK1 Q9BUB5 1/20 0.49
MKNK2 Q9HBH9 1/20 0.49
BCL2L1 Q07817 1/20 0.48
BAD Q92934 1/20 0.48
KDM4E B2RXH2 4/20 0.47
TDP1 Q9NUW8 1/20 0.47
TGFBR1 P36897 1/20 0.47
CAMKK2 Q96RR4 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 1/20 0.45
HSD17B10 Q99714 1/20 0.45
NAPRT Q6XQN6 1/20 0.44
DHODH Q02127 2/20 0.44
MAP2K4 P45985 2/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPK1 P28482 1/20 0.43
MAPK6 Q16659 1/20 0.43
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14886474 0.81 TRPV1 (0.57) TRPV1KDM4ESMN1; SMN2MAP2K4ALDH1A1
SCHEMBL6873637 0.81 KDM4E (0.56) MKNK1MKNK2KDM4ETDP1CAMKK2
SCHEMBL3554044 0.79 TRPV1 (0.61) TRPV1MKNK1MKNK2KDM4ETDP1
SCHEMBL3874091 0.79 TRPV1 (0.56) TRPV1MKNK1MKNK2KDM4ETDP1
SCHEMBL29604199 0.79 FEN1 (0.43) TRPV1KDM4ETDP1HSD17B10DHODH
SCHEMBL2639667 0.79 FEN1 (0.43) TRPV1KDM4ETDP1HSD17B10DHODH
SCHEMBL3881337 0.79 TRPV1 (0.65) TRPV1MAP2K4MAPK1MAPK6RORC
SCHEMBL28479998 0.78 TRPV1 (0.47) TRPV1KDM4EALDH1A1ATM
SCHEMBL14422898 0.78 PTGS1 (0.59) MKNK1MKNK2KDM4ETDP1CAMKK2
Hydrochloric Acid SCHEMBL3086577 0.78 TRPV1 (0.59) TRPV1MKNK1MKNK2KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748610-B2 Compounds as TRPV1 antagonists, pharmaceutical compositions and medical uses thereof FL THERAPEUTICS LLC (US) 2014-06-10 US disclosed
US-8748610-B2 Compounds as TRPV1 antagonists, pharmaceutical compositions and medical uses thereof FL THERAPEUTICS LLC (US) 2014-06-10 US disclosed
US-8748610-B2 Compounds as TRPV1 antagonists, pharmaceutical compositions and medical uses thereof FL THERAPEUTICS LLC (US) 2014-06-10 US disclosed
US-20120184509-A1 Compounds as TRVP1 Blockers, Pharmaceutical Compositions and Medical Uses Thereof ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) 2012-07-19 US disclosed
US-20120184509-A1 Compounds as TRVP1 Blockers, Pharmaceutical Compositions and Medical Uses Thereof ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) 2012-07-19 US disclosed
US-20120184509-A1 Compounds as TRVP1 Blockers, Pharmaceutical Compositions and Medical Uses Thereof ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184509-A1 Compounds as TRVP1 Blockers, Pharmaceutical Compositions and Medical Uses Thereof TRPV1, TRPV4, TRPV3 TTR 1854/4885TRPV1 1/4885MKNK1 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.